UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Poster #219 A POST-HOC ANALYSIS OF THE NEGATIVE SYMPTOM FACTOR SCORE IN A PROOF-OF-CONCEPT WITH A GLYCINE REUPTAKE INHIBITOR (GRI) IN SCHIZOPHRENIA

Schizophrenia research, 2012-04, Vol.136, p.S360-S360

2012

Volltextzugriff (PDF)

Examining the reliability and validity of the Clinical Assessment Interview for Negative Symptoms within the Management of Schizophrenia in Clinical Practice (MOSAIC) multisite national study

Schizophrenia research, 2017-07, Vol.185, p.137-143

2017

Volltextzugriff (PDF)

The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization

Schizophrenia research, 2015-08, Vol.166 (1), p.69-79

2015

Volltextzugriff (PDF)

Histologic outcomes in hepatitis C–infected patients with varying degrees of virologic response to interferon‐based treatments

Hepatology (Baltimore, Md.), 2010-10, Vol.52 (4), p.1193-1200

2010

Volltextzugriff (PDF)

Peginterferon alpha -2a Plus Ribavirin in Latino and Non-Latino Whites With HCV Genotype 1: Histologic Outcomes and Tolerability From the LATINO Study

The American journal of gastroenterology, 2010-10, Vol.105 (10), p.2177-2185

2010

Volltextzugriff (PDF)

Peginterferon α-2a Plus Ribavirin in Latino and Non-Latino Whites With HCV Genotype 1: Histologic Outcomes and Tolerability From the LATINO Study

The American journal of gastroenterology, 2010-10, Vol.105 (10), p.2177-2185

2010

Volltextzugriff (PDF)

Peginterferon [alpha]-2a Plus Ribavirin in Latino and Non-Latino Whites With HCV Genotype 1: Histologic Outcomes and Tolerability From the LATINO Study

The American journal of gastroenterology, 2010-10, Vol.105 (10), p.2177

2010

Volltextzugriff (PDF)

Association of Host Pharmacodynamic Effects with Virologic Response to Peginterferon Alfa-2a/Ribavirin in Chronic Hepatitis C

Hepatology (Baltimore, Md.), 2010-11, Vol.52 (6), p.1906-1914

2010

Volltextzugriff (PDF)

Peginterferon α-2a Plus Ribavirin in Latino and Non-Latino Whites With HCV Genotype 1: Histologic Outcomes and Tolerability From the LATI NO Study

The American journal of gastroenterology, 2010, Vol.105 (10), p.2177-2185

2010

Volltextzugriff (PDF)

Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa‐2a/ribavirin in chronic hepatitis C

Hepatology (Baltimore, Md.), 2010-12, Vol.52 (6), p.1906-1914

2010

Volltextzugriff (PDF)

535 Virologic and Metabolic Responses in Chronic Hepatitis C (CHC) Patients With Insulin Resistance (IR) Treated With Pioglitazone and Peginterferon Alfa-2a Plus Ribavirin

Gastroenterology (New York, N.Y. 1943), 2010, Vol.138 (5), p.S-790-S-790

2010

Volltextzugriff (PDF)

M1788 Identifying Patients Infected with HCV Genotype 1 Who May Benefit from Extended Peginterferon Alfa-2a/Ribavirin Therapy Beyond 48 Weeks

Gastroenterology (New York, N.Y. 1943), 2009, Vol.136 (5), p.A-838-A-838

2009

Volltextzugriff (PDF)

Peginterferon α-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon α-2b plus ribavirin: A pilot study of efficacy and safety

Digestive diseases and sciences, 2005-04, Vol.50 (4), p.719-726

2005

Volltextzugriff (PDF)

8 Histologic Outcomes in Non-SVR Patients with Varying Durations of HCV Undetectability After Interferon-Based Treatments

Gastroenterology (New York, N.Y. 1943), 2009, Vol.136 (5), p.A-790-A-790

2009

Volltextzugriff (PDF)

Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety

Digestive diseases and sciences, 2005-04, Vol.50 (4), p.719-726

2005

Volltextzugriff (PDF)

T1979 Association of Host Pharmacodynamic Effects and Virologic Response to Peginterferon Alfa-2a/Ribavirin in Patients With Chronic Hepatitis C

Gastroenterology (New York, N.Y. 1943), 2010, Vol.138 (5), p.S-841-S-841

2010

Volltextzugriff (PDF)

Pegylated interferon α-2a with or without ribavirin in HCV/HIV coinfection : Partially blinded, randomized multicenter trial

Digestive diseases and sciences, 2005-06, Vol.50 (6), p.1148-1155

2005

Volltextzugriff (PDF)

Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial

Digestive diseases and sciences, 2005-06, Vol.50 (6), p.1148

2005

Volltextzugriff (PDF)

Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti-inflammatory drug, in the treatment of osteoarthritis in dogs

Journal of the American Veterinary Medical Association, 1995-03, Vol.206 (6), p.807-811

1995

Volltextzugriff (PDF)

Pegylated Interferon [alpha] -2a With or Without Ribavirin in HCV/HIV Coinfection: Partially Blinded, Randomized Multicenter Trial

Digestive diseases and sciences, 2005-06, Vol.50 (6), p.1148-1155

2005

Volltextzugriff (PDF)

Peginterferon [alpha]-2a Combination Therapies in Chronic Hepatitis C Patients Who Relapsed After or Had a Viral Breakthrough on Therapy with Standard Interferon [alpha]-2b Plus Ribavirin: A Pilot Study of Efficacy and Safety

Digestive diseases and sciences, 2005-04, Vol.50 (4), p.719

2005

Volltextzugriff (PDF)

307 Peginterferon alfa-2A (40KD) (PEGASYS®) in combination with ribavirin in African American and Caucasian patients with chronic hepatitis C virus genotype 1 infection: Assessment of histologic response

Hepatology (Baltimore, Md.), 2003, Vol.38, p.303-303

2003

Volltextzugriff (PDF)

Determination of sulfadimethoxine withdrawal time from milk. Part II: Statistical assessment

Journal of AOAC International, 1995-03, Vol.78 (2), p.371-374

1995

Volltextzugriff (PDF)

Quick estimation of the three-parameter Weibull to describe tree size distributions

Forest ecology and management, 1985, Vol.13 (3), p.195-203

1985

Volltextzugriff (PDF)

Identification of and selection for optimal genotypes of goats in two diverse environments

Lentz, Ellen Lin

1989

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(38)
Dissertationen
(1)

Sprache

Englisch
(39)

Erscheinungsjahr

n.n

Thema

Female
(22)
Humans
(20)
Adult
(19)
Life Sciences & Biomedicine
(14)
Middle Aged
(14)
Science & Technology
(14)
Biological And Medical Sciences
(13)
Nursing
(12)
Adolescent
(10)
Medical Sciences
(10)
Premenstrual Syndrome - Psychology
(9)
Male
(8)
Severity Of Illness Index
(6)
Attitude To Health
(5)
Gastroenterology & Hepatology
(5)
Hepatitis C
(5)
Hepatitis C Virus
(5)
Recombinant Proteins
(5)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(4)
Antiviral Agents
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Poster #219 A POST-HOC ANALYSIS OF THE NEGATIVE SYMPTOM FACTOR SCORE IN A PROOF-OF-CONCEPT WITH A GLYCINE REUPTAKE INHIBITOR (GRI) IN SCHIZOPHRENIA

Examining the reliability and validity of the Clinical Assessment Interview for Negative Symptoms within the Management of Schizophrenia in Clinical Practice (MOSAIC) multisite national study

The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization

Histologic outcomes in hepatitis C–infected patients with varying degrees of virologic response to interferon‐based treatments

Peginterferon alpha -2a Plus Ribavirin in Latino and Non-Latino Whites With HCV Genotype 1: Histologic Outcomes and Tolerability From the LATINO Study

Peginterferon α-2a Plus Ribavirin in Latino and Non-Latino Whites With HCV Genotype 1: Histologic Outcomes and Tolerability From the LATINO Study

Peginterferon [alpha]-2a Plus Ribavirin in Latino and Non-Latino Whites With HCV Genotype 1: Histologic Outcomes and Tolerability From the LATINO Study

Association of Host Pharmacodynamic Effects with Virologic Response to Peginterferon Alfa-2a/Ribavirin in Chronic Hepatitis C

Peginterferon α-2a Plus Ribavirin in Latino and Non-Latino Whites With HCV Genotype 1: Histologic Outcomes and Tolerability From the LATI NO Study

Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa‐2a/ribavirin in chronic hepatitis C

535 Virologic and Metabolic Responses in Chronic Hepatitis C (CHC) Patients With Insulin Resistance (IR) Treated With Pioglitazone and Peginterferon Alfa-2a Plus Ribavirin

M1788 Identifying Patients Infected with HCV Genotype 1 Who May Benefit from Extended Peginterferon Alfa-2a/Ribavirin Therapy Beyond 48 Weeks

Peginterferon α-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon α-2b plus ribavirin: A pilot study of efficacy and safety

8 Histologic Outcomes in Non-SVR Patients with Varying Durations of HCV Undetectability After Interferon-Based Treatments

Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety

T1979 Association of Host Pharmacodynamic Effects and Virologic Response to Peginterferon Alfa-2a/Ribavirin in Patients With Chronic Hepatitis C

Pegylated interferon α-2a with or without ribavirin in HCV/HIV coinfection : Partially blinded, randomized multicenter trial

Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial

Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti-inflammatory drug, in the treatment of osteoarthritis in dogs

Pegylated Interferon [alpha] -2a With or Without Ribavirin in HCV/HIV Coinfection: Partially Blinded, Randomized Multicenter Trial

Peginterferon [alpha]-2a Combination Therapies in Chronic Hepatitis C Patients Who Relapsed After or Had a Viral Breakthrough on Therapy with Standard Interferon [alpha]-2b Plus Ribavirin: A Pilot Study of Efficacy and Safety

307 Peginterferon alfa-2A (40KD) (PEGASYS®) in combination with ribavirin in African American and Caucasian patients with chronic hepatitis C virus genotype 1 infection: Assessment of histologic response

Determination of sulfadimethoxine withdrawal time from milk. Part II: Statistical assessment

Quick estimation of the three-parameter Weibull to describe tree size distributions

Identification of and selection for optimal genotypes of goats in two diverse environments

Suchergebnisse filtern